Thyroid cancer: Current molecular perspectives

Journal of Oncology

Volumn , Issue , 2010, Pages

  Brandi, Maria Luisa ^a   Giusti, Francesca ^a   Falchetti, Alberto ^a   Franceschelli, Francesco ^a   Marini, Francesca ^a   Tanini, Annalisa ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; 4 AMINO 7 TERT BUTYL 5 (4 METHYLPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; AAL 881; ANTINEOPLASTIC AGENT; B RAF KINASE; BETA CATENIN; CEP 751; CETUXIMAB; EEE 788; GROWTH FACTOR RECEPTOR; INDOLIZINE DERIVATIVE; LBT 613; LESTAURTINIB; MICRORNA; MITOCHONDRIAL DNA; MITOGEN ACTIVATED PROTEIN KINASE; MOTESANIB; NEUROTROPHIC TYROSINE KINASE RECEPTOR 1; NUCLEAR PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P53; PROTEIN PATCHED; PROTEIN RET; RAS PROTEIN; RPI 1; SORAFENIB; SU 12248; SUNITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB;

AGE DISTRIBUTION; ANTINEOPLASTIC ACTIVITY; BODY MASS; CANCER MORTALITY; CLINICAL FEATURE; CLINICAL TRIAL; DRUG EFFICACY; ENVIRONMENTAL FACTOR; ETHNIC DIFFERENCE; FAMILY HISTORY; FOOD INTAKE; GENDER; GENE MUTATION; GENE REARRANGEMENT; GENETIC ASSOCIATION; GENOTYPE PHENOTYPE CORRELATION; GOITER; HEREDITY; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HYPERTHYROIDISM; IONIZING RADIATION; MOLECULAR GENETICS; NONHUMAN; PROGNOSIS; PROSPECTIVE STUDY; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; THYROID CANCER; THYROID CARCINOMA; THYROID DISEASE; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID MICROCARCINOMA; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY;

EID: 77951673111     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2010/351679     Document Type: Review

References (204)

1. Edwards B. K., Brown M. L., Wingo P. A., Annual report to the nation on the status of cancer, 19752002, featuring population-based trends in cancer treatment Journal of the National Cancer Institute 2005 97 19 1407 1427
2. Chen A. Y., Jemal A., Ward E. M., Increasing incidence of differentiated thyroid cancer in the United States, 19882005 Cancer 2009 115 16 3801 3807
3. Cooper D. S., Doherty G. M., Haugen B. R., Management guidelines for patients with thyroid nodules and differentiated thyroid cancer Thyroid 2006 16 2 109 141
4. De Lellis R. A., Lloyd R. V., Heitz P. U., Eng C., World Health Organization International Classification of Tumors. Pathology and Genetics of Tumors of Endocrine Organs 2004 Lyon, France IARC Press
5. Hay I. D., Papillary thyroid carcinoma Endocrinology and Metabolism Clinics of North America 1990 19 3 545 576
6. Cooper D. S., Schneyer C. R., Follicular and Hurthle cell carcinoma of the thyroid Endocrinology and Metabolism Clinics of North America 1990 19 3 577 591
7. Chiacchio S., Lorenzoni A., Boni G., Rubello D., Elisei R., Mariani G., Anaplastic thyroid cancer: prevalence, diagnosis and treatment Minerva Endocrinologica 2008 33 4 341 357
8. Harach H. R., Franssila K. O., Wasenius V.-M., Occult papillary carcinoma of the thyroid. A normal finding in Finland. A systematic autopsy study Cancer 1985 56 3 531 538
9. Franceschi S., Boyle P., Maisonneuve P., The epidemiology of thyroid carcinoma Critical Reviews in Oncogenesis 1993 4 1 25 52
10. Landis S. H., Murray T., Bolden S., Wingo P. A., Cancer statistics CA: A Cancer Journal for Clinicians 1998 48 6 329
11. Belfiore A., La Rosa G. L., La Porta G. A., Cancer risk in patients with cold thyroid nodules: relevance of iodine intake, sex, age, and multinodularity American Journal of Medicine 1992 93 4 363 369
12. Parkin D. M., Whelan S. L., Ferlay J., Powell J., Teppo L., Cancer Incidence in Five Continents 2003 8 Lyon, France IARC Press IARC Scientific Publication no. 155
13. Hanson G. A., Komorowski R. A., Cerletty J. M., Wilson S. D., Thyroid gland morphology in young adults: normal subjects versus those with prior low-dose neck irradiation in childhood Surgery 1983 94 6 984 988
14. Pui C.-H., Cheng C., Leung W., Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia The New England Journal of Medicine 2003 349 7 640 649 (Pubitemid 36975996)
15. Hancock S. L., Cox R. S., McDougall I. R., Thyroid diseases after treatment of Hodgkins disease The New England Journal of Medicine 1991 325 9 599 605
16. Ron E., Lubin J. H., Shore R. E., Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies Radiation Research 1995 141 3 259 277
17. Nikiforov Y., Gnepp D. R., Pediatric thyroid cancer after the Chernobyl disaster: pathomorphologic study of 84 cases (1991-1992) from the Republic of Belarus Cancer 1994 74 2 748 766 (Pubitemid 24217643)
18. Leenhardt L., Aurengo A., Post-Chernobyl thyroid carcinoma in children Best Practice and Research: Clinical Endocrinology and Metabolism 2000 14 4 667 677 (Pubitemid 32293861)
19. Farbota L. M., Calandra D. B., Lawrence A. M., Paloyan E., Thyroid carcinoma in Graves disease Surgery 1985 98 6 1148 1153
20. Pacini F., Elisei R., Di Coscio G. C., Thyroid carcinoma in thyrotoxic patients treated by surgery Journal of Endocrinological Investigation 1988 11 2 107 112 (Pubitemid 18070528)
21. Pellegriti G., Belfiore A., Giuffrida D., Lupo L., Vigneri R., Outcome of differentiated thyroid cancer in Graves patients Journal of Clinical Endocrinology and Metabolism 1998 83 8 2805 2809 (Pubitemid 28493780)
22. Segal K., Ben-Bassat M., Avraham A., Har-El G., Sidi J., Hashimotos thyroiditis and carcinoma of the thyroid gland International Surgery 1985 70 3 205 209 (Pubitemid 16131950)
23. Holm L. E., Blomgren H., Lowhagen T., Cancer risks in patients with chronic lymphocytic thyroiditis The New England Journal of Medicine 1985 312 10 601 604 (Pubitemid 15133674)
24. Dal Maso L., Vecchia C. L., Franceschi S., A pooled analysis of thyroid cancer studies. V. Anthropometric factors Cancer Causes and Control 2000 11 2 137 144 (Pubitemid 30088392)
25. Suzuki T., Matsuo K., Hasegawa Y., Anthropometric factors at age 20 years and risk of thyroid cancer Cancer Causes and Control 2008 19 10 1233 1242
26. Negri E., Dal Maso L., Ron E., A pooled analysis of case-control studies of thyroid cancer. II. Menstrual and reproductive factors Cancer Causes and Control 1999 10 2 143 155 (Pubitemid 29161106)
27. Franceschi S., Preston-Martin S., Dal Maso L., A pooled analysis of case-control studies of thyroid cancer. IV. Benign thyroid diseases Cancer Causes and Control 1999 10 6 583 595
28. Goodman M. T., Kolonel L. N., Wilkens L. R., The association of body size, reproductive factors and thyroid cancer British Journal of Cancer 1992 66 6 1180 1184
29. Ron E., Lunenfeld B., Menczer J., Cancer incidence in a cohort of infertile women American Journal of Epidemiology 1987 125 5 789 790
30. Malchoff C. D., Malchoff D. M., Familial papillary thyroid carcinoma Cancer Treatment and Research 2004 122 381 387
31. Li Volsi V. A., Albores-Saavedra J., Asa S. L., DeLellis R. A., Lloyd R. V., Heitz P. U., Eng C., Papillary carcinoma Tumors of Endocrine Organs 2004 57 66 World Health Organization Classification of Tumors
32. Harach H. R., Williams G. T., Williams E. D., Familial adenomatous polyposis associated thyroid carcinoma: a distinct type of follicular cell neoplasm Histopathology 1994 25 6 549 561
33. Pilarski R., Cowden syndrome: a critical review of the clinical literature Journal of Genetic Counseling 2009 18 1 13 27
34. Kirschner L. S., Sandrini F., Monbo J., Lin J.-P., Carney J. A., Stratakis C. A., Genetic heterogeneity and spectrum of mutations of the PRKAR1A gene in patients with the Carney complex Human Molecular Genetics 2000 9 20 3037 3046 (Pubitemid 32000777)
35. Casey M., Vaughan C. J., He J., Mutations in the protein kinase A R1 regulatory subunit cause familial cardiac myxomas and Carney complex Journal of Clinical Investigation 2000 106 5 R31 R38
36. Bertherat J., Horvath A., Groussin L., Mutations in regulatory subunit type 1A of cyclic adenosine 5′ -monophosphate-dependent protein kinase (PRKAR1A): phenotype analysis in 353 patients and 80 different genotypes Journal of Clinical Endocrinology and Metabolism 2009 94 6 2085 2091
37. Sandrini F., Matyakhina L., Sarlis N. J., Regulatory subunit type I- of protein kinase A (PRKARIA): a tumor-suppressor gene for sporadic thyroid cancer Genes Chromosomes and Cancer 2002 35 2 182 192 (Pubitemid 34919976)
38. Kirschner L. S., Kusewitt D. F., Matyakhina L., A mouse model for the carney complex tumor syndrome develops neoplasia in cyclic AMP-responsive tissues Cancer Research 2005 65 11 4506 4514 (Pubitemid 40740784)
39. Peyssonnaux C., Eychene A., The Raf/MEK/ERK pathway: new concepts of activation Biology of the Cell 2001 93 1-2 53 62 (Pubitemid 33040860)
40. Drijard B., Raingeaud J., Barrett T., Independent human MAP kinase signal transduction pathways defined by MEK and MKK isoforms Science 1995 267 5198 682 685
41. Pearson G., Robinson F., Beers Gibson T., Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions Endocrine Reviews 2001 22 2 153 183 (Pubitemid 32458157)
42. Kimura E. T., Nikiforova M. N., Zhu Z., Knauf J. A., Nikiforov Y. E., Fagin J. A., High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma Cancer Research 2003 63 7 1454 1457 (Pubitemid 36373628)
43. Xing M., BRAF mutation in thyroid cancer Endocrine-Related Cancer 2005 12 2 245 262 (Pubitemid 40896444)
44. Cohen Y., Xing M., Mambo E., BRAF mutation in papillary thyroid carcinoma Journal of the National Cancer Institute 2003 95 8 625 627 (Pubitemid 36553510)
45. Karasarides M., Chiloeches A., Hayward R., B-RAF is a therapeutic target in melanoma Oncogene 2004 23 37 6292 6298
46. Wan P. T. C., Garnett M. J., Roe S. M., Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF Cell 2004 116 6 855 867
47. Adeniran A. J., Zhu Z., Gandhi M., Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas American Journal of Surgical Pathology 2006 30 2 216 222
48. Trovisco V., Vieira de Castro I., Soares P., BRAF mutations are associated with some histological types of papillary thyroid carcinoma Journal of Pathology 2004 202 2 247 251
49. Carta C., Moretti S., Passeri L., Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAFV599Ins) Clinical Endocrinology 2006 64 1 105 109
50. Hou P., Liu D., Xing M., Functional characterization of the T1799-1801del and A1799-1816ins BRAF mutations in papillary thyroid cancer Cell Cycle 2007 6 3 377 379
51. Ciampi R., Knauf J. A., Kerler R., Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer Journal of Clinical Investigation 2005 115 1 94 101
52. http://www.ncbi.nlm.nih.gov/sites/entrez?Db=geneCmd= ShowDetailViewTermToSearch=10142
53. Nikiforova M. N., Kimura E. T., Gandhi M., BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas Journal of Clinical Endocrinology and Metabolism 2003 88 11 5399 5404
54. Namba H., Nakashima M., Hayashi T., Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers Journal of Clinical Endocrinology and Metabolism 2003 88 9 4393 4397
55. Xing M., Westra W. H., Tufano R. P., BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer Journal of Clinical Endocrinology and Metabolism 2005 90 12 6373 6379
56. Fugazzola L., Mannavola D., Cirello V., BRAF mutations in an Italian cohort of thyroid cancers Clinical Endocrinology 2004 61 2 239 243
57. Trovisco V., Soares P., Preto A., Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients age but not with tumour aggressiveness Virchows Archiv 2005 446 6 589 595
58. Kim T. Y., Kim W. B., Rhee Y. S., The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma Clinical Endocrinology 2006 65 3 364 368
59. Riesco-Eizaguirre G., Gutirrez-Martnez P., Garca-Cabezas M. A., Nistal M., Santisteban P., The oncogene BRAFV600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na targeting to the membrane Endocrine-Related Cancer 2006 13 1 257 269
60. Begum S., Rosenbaum E., Henrique R., Cohen Y., Sidransky D., Westra W. H., BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment Modern Pathology 2004 17 11 1359 1363
61. Knauf J. A., Ma X., Smith E. P., Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation Cancer Research 2005 65 10 4238 4245
62. Liu R.-T., Hou C.-Y., You H.-L., Selective occurrence of RAS mutations in benign and malignant thyroid follicular neoplasms in Taiwan Thyroid 2004 14 8 616 621
63. Namba H., Rubin S. A., Fagin J. A., Point mutations of RAS oncogenes are an early event in thyroid tumorigenesis Molecular Endocrinology 1990 4 10 1474 1479
64. Ezzat S., Zheng L., Kolenda J., Safarian A., Freeman J. L., Asa S. L., Prevalence of activating RAS mutations in morphologically characterized thyroid nodules Thyroid 1996 6 5 409 416
65. Vasko V. V., Gaudart J., Allasia C., Thyroid follicular adenomas may display features of follicular carcinoma and follicular variant of papillary carcinoma European Journal of Endocrinology 2004 151 6 779 786
66. Lemoine N. R., Mayall E. S., Wyllie F. S., High frequency of RAS oncogene activation in all stages of human thyroid tumorigenesis Oncogene 1989 4 2 159 164
67. Suarez H. G., du Villard J. A., Severino M., Presence of mutations in all three RAS genes in human thyroid tumors Oncogene 1990 5 4 565 570
68. Esapa C. T., Johnson S. J., Kendall-Taylor P., Lennard T. W. J., Harris P. E., Prevalence of RAS mutations in thyroid neoplasia Clinical Endocrinology 1999 50 4 529 535
69. Motoi N., Sakamoto A., Yamochi T., Horiuchi H., Motoi T., Machinami R., Role of RAS mutation in the progression of thyroid carcinoma of follicular epithelial origin Pathology Research and Practice 2000 196 1 1 7
70. Basolo F., Pisaturo F., Pollina L. E., N-RAS mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression Thyroid 2000 10 1 19 23
71. Schark C., Fulton N., Jacoby R. F., Westbrook C. A., Straus F. H. II, Kaplan E. L., N-RAS 61 oncogene mutations in Hurthle cell tumors Surgery 1990 108 6 994 1000
72. Tallini G., Hsueh A., Liu S., Garcia-Rostan G., Speicher M. R., Ward D. C., Frequent chromosomal DNA unbalance in thyroid oncocytic (Hurthle cell) neoplasms detected by comparative genomic hybridization Laboratory Investigation 1999 79 5 547 555
73. Asakawa H., Kobayashi T., Multistep carcinogenesis in anaplastic thyroid carcinoma: a case report Pathology 2002 34 1 94 97
74. Adeniran A. J., Zhu Z., Gandhi M., Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas American Journal of Surgical Pathology 2006 30 2 216 222
75. Zhu Z., Gandhi M., Nikiforova M. N., Fischer A. H., Nikiforov Y. E., Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma: an unusually high prevalence of RAS mutations American Journal of Clinical Pathology 2003 120 1 71 77
76. Hara H., Fulton N., Yashiro T., N-RAS mutation: an independent prognostic factor for aggressiveness of papillary thyroid carcinoma Surgery 1994 116 6 1010 1016
77. Garcia-Rostan G., Zhao H., Camp R. L., RAS mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer Journal of Clinical Oncology 2003 21 17 3226 3235
78. Karga H., Lee J.-K., Vickery A. L. Jr., Thor A., Gaz R. D., Jameson J. L., RAS oncogene mutations in benign and malignant thyroid neoplasms Journal of Clinical Endocrinology and Metabolism 1991 73 4 832 836 (Pubitemid 21921945)
79. Manenti G., Pilotti S., Re F. C., Della Porta G., Pierotti M. A., Selective activation of RAS oncogenes in follicular and undifferentiated thyroid carcinomas European Journal of Cancer A 1994 30 7 987 993 (Pubitemid 24256250)
80. Fagin J. A., Minireview: branded from the start-distinct oncogenic initiating events may determine tumor fate in the thyroid Molecular Endocrinology 2002 16 5 903 911
81. Saavedra H. I., Knauf J. A., Shirokawa J. M., The RAS oncogene induces genomic instability in thyroid PCCL3 cells via the MAPK pathway Oncogene 2000 19 34 3948 3954
82. Takahashi M., Buma Y., Iwamoto T., Inaguma Y., Ikeda H., Hiai H., Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains Oncogene 1988 3 5 571 578 (Pubitemid 19003664)
83. Robertson K., Mason I., The GDNF-KET signalling partnership Trends in Genetics 1997 13 1 1 3 (Pubitemid 127739941)
84. Marshall C. J., Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation Cell 1995 80 2 179 185
85. Tallini G., Santoro M., Helie M., RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes Clinical Cancer Research 1998 4 2 287 294 (Pubitemid 28122740)
86. Gagel R. F., Marx S. J., Larsen P. R., Kronenberg H., Melmed S., Polonsky K. S., Multiple endocrine neoplasia Book Multiple Endocrine Neoplasia 2003 10th Philadelphia, Pa, USA W. B. Saunders 1762 1771
87. Brandi M. L., Gagel R. F., Angeli A., Consensus: guidelines for diagnosis and therapy of MEN type 1 and type 2 Journal of Clinical Endocrinology and Metabolism 2001 86 12 5658 5671 (Pubitemid 33152604)
88. Mulligan L. M., Marsh D. J., Robinson B. G., Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium Journal of Internal Medicine 1995 238 4 343 346
89. Santoro M., Melillo R. M., Carlomagno F., Molecular biology of the MEN2 gene Journal of Internal Medicine 1998 243 6 505 508
90. Hansford J. R., Mulligan L. M., Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis Journal of Medical Genetics 2000 37 11 817 827
91. Eng C., Mulligan L. M., Smith D. P., Low frequency of germline mutations in the RET protooncogene in patients with apparently sporadic medullary thyroid carcinoma Clinical Endocrinology 1995 43 1 123 127
92. Decker R. A., Peacock M. L., Borst M. J., Progress in genetic screening of multiple endocrine neoplasia type 2A: is calcitonin testing obsolete? Surgery 1995 118 2 257 264
93. Kitamura Y., Goodfellow P. J., Shimizu K., Novel germline RET proto-oncogene mutations associated with medullary thyroid carcinoma (MTC): mutation analysis in Japanese patients with MTC Oncogene 1997 14 25 3103 3106
94. Lips C. J. M., Clinical management of the multiple endocrine neoplasia syndromes: results of a computerized opinion poll at the Sixth International Workshop on Multiple Endocrine Neoplasia and von Hippel-Lindau Disease Journal of Internal Medicine 1998 243 6 589 594
95. Eng C., Mulligan L. M., Healey C. S., Heterogeneous mutation of the RET proto-oncogene in subpopulations of medullary thyroid carcinoma Cancer Research 1996 56 9 2167 2170 (Pubitemid 26119920)
96. Alberti L., Carniti C., Miranda C., Roccato E., Pierotti M. A., RET and NTRK1 proto-oncogenes in human diseases Journal of Cellular Physiology 2003 195 2 168 186
97. Frank-Raue K., Machens A., Scheuba C., Niederle B., Dralle H., Raue F., Difference in development of medullary thyroid carcinoma among carriers of RET mutations in codons 790 and 791 Clinical Endocrinology 2008 69 2 259 263
98. Wiench M., Wygoda Z., Gubala E., Estimation of risk of inherited medullary thyroid carcinoma in apparent sporadic patients Journal of Clinical Oncology 2001 19 5 1374 1380
99. Vierhapper H., Bieglmayer C., Heinze G., Baumgartner-Parzer S., Frequency of RET proto-oncogene mutations in patients with normal and with moderately elevated pentagastrin-stimulated serum concentrations of calcitonin Thyroid 2004 14 8 580 583
100. Machens A., Niccoli-Sire P., Hoegel J., Early malignant progression of hereditary medullary thyroid cancer The New England Journal of Medicine 2003 349 16 1517 1525
101. Colombo-Benkmann M., Li Z., Riemann B., Characterization of the RET protooncogene transmembrane domain mutation S649L associated with nonaggressive medullary thyroid carcinoma European Journal of Endocrinology 2008 158 6 811 816
102. Greco A., Roccato E., Pierotti M. A., TRK oncogenes in papillary thyroid carcinoma Cancer Treatment and Research 2004 122 207 219
103. Bongarzone I., Vigneri P., Mariani L., Collini P., Pilotti S., Pierotti M. A., RET/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: correlation with clinicopathological features Clinical Cancer Research 1998 4 1 223 228
104. Cantley L. C., Neel B. G., New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway Proceedings of the National Academy of Sciences of the United States of America 1999 96 8 4240 4245
105. Garca-Rostn G., Costa A. M., Pereira-Castro I., Mutation of the PIK3CA gene in anaplastic thyroid cancer Cancer Research 2005 65 22 10199 10207
106. Hou P., Liu D., Shan Y., Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer Clinical Cancer Research 2007 13 4 1161 1170
107. Wang Y., Hou P., Yu H., High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/Akt pathway in thyroid tumors Journal of Clinical Endocrinology and Metabolism 2007 92 6 2387 2390
108. Dahia P. L. M., Marsh D. J., Zheng Z., Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors Cancer Research 1997 57 21 4710 4713
109. Moretti F., Farsetti A., Soddu S., p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells Oncogene 1997 14 6 729 740
110. Fagin J. A., Tang S.-H., Zeki K., Di Lauro R., Fusco A., Gonsky R., Reexpression of thyroid peroxidase in a derivative of an undifferentiated thyroid carcinoma cell line by introduction of wild-type p53 Cancer Research 1996 56 4 765 771
111. Fagin J. A., Matsuo K., Karmakar A., Chen D. L., Tang S.-H., Koeffler H. P., High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas Journal of Clinical Investigation 1993 91 1 179 184
112. Donghi R., Longoni A., Pilotti S., Michieli P., Della Porta G., Pierotti M. A., Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland Journal of Clinical Investigation 1993 91 4 1753 1760
113. Dobashi Y., Sugimura H., Sakamoto A., Stepwise participation of p53 gene mutation during dedifferentiation of human thyroid carcinomas Diagnostic Molecular Pathology 1994 3 1 9 14
114. Ho Y.-S., Tseng S.-C., Chin T.-Y., Hsieh L.-L., Lin J.-D., p53 gene mutation in thyroid carcinoma Cancer Letters 1996 103 1 57 63
115. Takeuchi Y., Daa T., Kashima K., Yokoyama S., Nakayama I., Noguchi S., Mutations of p53 in thyroid carcinoma with an insular component Thyroid 1999 9 4 377 381
116. Kraus C., Liehr T., Hlsken J., Localization of the human -catenin gene (CTNNB1) to 3p21: a region implicated in tumor development Genomics 1994 23 1 272 274 (Pubitemid 24296969)
117. Van Hengel J., Nollet F., Berx G., van Roy N., Speleman F., van Roy F., Assignment of the human -catenin gene (CTNNB1) to 3p22→p21.3 by fluorescence in situ hybridization Cytogenetics and Cell Genetics 1995 70 1-2 68 70
118. Lie D.-C., Colamarino S. A., Song H.-J., Wnt signalling regulates adult hippocampal neurogenesis Nature 2005 437 7063 1370 1375
119. Garcia-Rostan G., Camp R. L., Herrero A., Carcangiu M. L., Rimm D. L., Tallini G., -catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis American Journal of Pathology 2001 158 3 987 996 (Pubitemid 32221790)
120. Miyake N., Maeta H., Horie S., Absence of mutations in the -catenin and adenomatous polyposis coli genes in papillary and follicular thyroid carcinomas Pathology International 2001 51 9 680 685 (Pubitemid 32989613)
121. Mximo V., Soares P., Lima J., Cameselle-Teijeiro J., Sobrinho-Simes M., Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNA variants in human thyroid pathology: a study with emphasis on Hurthle cell tumors American Journal of Pathology 2002 160 5 1857 1865 (Pubitemid 34525665)
122. Mximo V., Botelho T., Capela J., Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hurthle cell) tumours of the thyroid British Journal of Cancer 2005 92 10 1892 1898 (Pubitemid 40826138)
123. Grieco M., Santoro M., Berlingieri M. T., PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas Cell 1990 60 4 557 563 (Pubitemid 20083812)
124. Santoro M., Dathan N. A., Berlingieri M. T., Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma Oncogene 1994 9 2 509 516 (Pubitemid 24041530)
125. Bongarzone I., Monzini N., Borrello M. G., Molecular characterization of a thyroid tumor-specific transforming sequence formed by the fusion of ret tyrosine kinase and the regulatory subunit RI of cyclic AMP-dependent protein kinase A Molecular and Cellular Biology 1993 13 1 358 366 (Pubitemid 23006913)
126. Fugazzola L., Pierotti M. A., Vigano E., Pacini F., Vorontsova T. V., Bongarzone I., Molecular and biochemical analysis of RET/PTC4, a novel oncogenic rearrangement between RET and ELE1 genes, in a post-Chernobyl papillary thyroid cancer Oncogene 1996 13 5 1093 1097 (Pubitemid 26329096)
127. Nikiforov Y. E., Rowland J. M., Bove K. E., Monforte-Munoz H., Fagin J. A., Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children Cancer Research 1997 57 9 1690 1694
128. Soares P., Fonseca E., Wynford-Thomas D., Sobrinho-Simes M., Sporadic ret-rearranged papillary carcinoma of the thyroid: a subset of slow growing, less aggressive thyroid neoplasms? Journal of Pathology 1998 185 1 71 78
129. Rabes H. M., Demidchik E. P., Sidorow J. D., Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-chernobyl papillary thyroid carcinomas: biological, phenotypic, and clinical implications Clinical Cancer Research 2000 6 3 1093 1103
130. Fenton C. L., Lukes Y., Nicholson D., Dinauer C. A., Francis G. L., Tuttle R. M., The ret/PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adults Journal of Clinical Endocrinology and Metabolism 2000 85 3 1170 1175
131. Nakata T., Kitamura Y., Shimizu K., Fusion of a novel gene, ELKS, to RET due to translocation t(10;12)(q11;p13) in a papillary thyroid carcinoma Genes Chromosomes and Cancer 1999 25 2 97 103
132. Ciampi R., Giordano T. J., Wikenheiser-Brokamp K., Koenig R. J., Nikiforov Y. E., HOOK3-RET: a novel type of RET/PTC rearrangement in papillary thyroid carcinoma Endocrine-Related Cancer 2007 14 2 445 452
133. Knauf J. A., Kuroda H., Basu S., Fagin J. A., RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase Oncogene 2003 22 28 4406 4412
134. Ravichandran K. S., Signaling via Shc family adapter proteins Oncogene 2001 20 44 6322 6330
135. Tallini G., Asa S. L., RET oncogene activation in papillary thyroid carcinoma Advances in Anatomic Pathology 2001 8 6 345 354
136. Nikiforov Y. E., RET/PTC rearrangement in thyroid tumors Endocrine Pathology 2002 13 1 3 16
137. Viglietto G., Chiappetta G., Martinez-Tello F. J., RET/PTC oncogene activation is an early event in thyroid carcinogenesis Oncogene 1995 11 6 1207 1210
138. Sheils O. M., OEary J. J., Uhlmann V., Luttich K., Sweeney E. C., ret/PTC-1 activation in Hashimoto thyroiditis International Journal of Surgical Pathology 2000 8 3 185 189
139. Elisei R., Romei C., Vorontsova T., RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults Journal of Clinical Endocrinology and Metabolism 2001 86 7 3211 3216
140. Cheung C. C., Carydis B., Ezzat S., Bedard Y. C., Asa S. L., Analysis of ret/PTC gene rearrangements refines the fine needle aspiration diagnosis of thyroid cancer Journal of Clinical Endocrinology and Metabolism 2001 86 5 2187 2190
141. Kroll T. G., Sarraf P., Pecciarini L., PAX8-PPAR 1 fusion in oncogene human thyroid carcinoma Science 2000 289 5483 1357 1360
142. French C. A., Alexander E. K., Cibas E. S., Genetic and biological subgroups of low-stage follicular thyroid cancer American Journal of Pathology 2003 162 4 1053 1060
143. Nikiforova M. N., Lynch R. A., Biddinger P. W., RAS point mutations and PAX8-PPAR rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma Journal of Clinical Endocrinology and Metabolism 2003 88 5 2318 2326
144. Dwight T., Thoppe S. R., Foukakis T., Involvement of the PAX8/peroxisome proliferator-activated receptor rearrangement in follicular thyroid tumors Journal of Clinical Endocrinology and Metabolism 2003 88 9 4440 4445
145. Marques A. R., Espadinha C., Catarino A. L., Expression of PAX8-PPAR 1 rearrangements in both follicular thyroid carcinomas and adenomas Journal of Clinical Endocrinology and Metabolism 2002 87 8 3947 3952
146. Nikiforova M. N., Biddinger P. W., Caudill C. M., Kroll T. G., Nikiforov Y. E., PAX8-PPAR rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses American Journal of Surgical Pathology 2002 26 8 1016 1023
147. Gregory Powell J., Wang X., Allard B. L., The PAX8/PPAR fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPAR inhibition Oncogene 2004 23 20 3634 3641
148. Giordano T. J., Au A. Y. M., Kuick R., Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation Clinical Cancer Research 2006 12 7 1983 1993
149. Reddi H. V., McIver B., Grebe S. K. G., Eberhardt N. L., Minireview: the paired box-8/peroxisome proliferator-activated receptor- oncogene in thyroid tumorigenesis Endocrinology 2007 148 3 932 935
150. Ward L. S., Brenta G., Medvedovic M., Fagin J. A., Studies of allelic loss in thyroid tumors reveal major differences in chromosomal instability between papillary and follicular carcinomas Journal of Clinical Endocrinology and Metabolism 1998 83 2 525 530
151. Hunt J. L., Livolsi V. A., Baloch Z. W., A novel microdissection and genotyping of follicular-derived thyroid tumors to predict aggressiveness Human Pathology 2003 34 4 375 380
152. Rodrigues-Serpa A., Catarino A., Soares J., Loss of heterozygosity in follicular and papillary thyroid carcinomas Cancer Genetics and Cytogenetics 2003 141 1 26 31
153. Hunt J. L., Yim J. H., Carty S. E., Fractional allelic loss of tumor suppressor genes identifies malignancy and predicts clinical outcome in follicular thyroid tumors Thyroid 2006 16 7 643 649
154. Zedenius J., Wallin G., Svensson A., Allelotyping of follicular thyroid tumors Human Genetics 1995 96 1 27 32
155. Tung W. S., Shevlin D. W., Kaleem Z., Tribune D. J., Wells S. A. Jr., Goodfellow P. J., Allelotype of follicular thyroid carcinomas reveals genetic instability consistent with frequent nondisjunctional chromosomal loss Genes Chromosomes and Cancer 1997 19 1 43 51
156. Segev D. L., Saji M., Phillips G. S., Polymerase chain reaction-based microsatellite polymorphism analysis of follicular and Hurthle cell neoplasms of the thyroid Journal of Clinical Endocrinology and Metabolism 1998 83 6 2036 2042
157. Hunt J. L., Yim J. H., Tometsko M., Loss of heterozygosity of the VHL gene identifies malignancy and predicts death in follicular thyroid tumors Surgery 2003 134 6 1043 1048
158. Israel A., Sharan R., Ruppin E., Galun E., Increased MicroRNA activity in human cancers PLoS One 2009 4 6, article e6045
159. Jazdzewski K., Liyanarachchi S., Swierniak M., Polymorphic mature microRNAs from passenger strand of pre-miR-146a contribute to thyroid cancer Proceedings of the National Academy of Sciences of the United States of America 2009 106 5 1502 1505
160. Pallante P., Visone R., Ferracin M., MicroRNA deregulation in human thyroid papillary carcinomas Endocrine-Related Cancer 2006 13 2 497 508
161. Kim H. J., Kim Y. H., Lee D. S., Chung J.-K., Kim S., In vivo imaging of functional targeting of miR-221 in papillary thyroid carcinoma Journal of Nuclear Medicine 2008 49 10 1686 1693
162. Nikiforova M. N., Chiosea S. I., Nikiforov Y. E., MicroRNA expression profiles in thyroid tumors Endocrine Pathology 2009 20 2 85 91
163. Galang C. K., Hauser C. A., Cooperative DNA binding of the highly conserved human Hox 2.1 homeodomain gene product The New Biologist 1992 4 5 558 568
164. Lyons J. F., Wilhelm S., Hibner B., Bollag G., Discovery of a novel Raf kinase inhibitor Endocrine-Related Cancer 2001 8 3 219 225
165. Wilhelm S. M., Carter C., Tang L., BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Research 2004 64 19 7099 7109
166. Wan P. T. C., Garnett M. J., Roe S. M., Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF Cell 2004 116 6 855 867
167. Baudin E., Schlumberger M., New therapeutic approaches for metastatic thyroid carcinoma Lancet Oncology 2007 8 2 148 156
168. Ouyang B., Knauf J. A., Smith E. P., Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo Clinical Cancer Research 2006 12 6 1785 1793
169. Kodama Y., Asai N., Kawai K., The RET proto-oncogene: a molecular therapeutic target in thyroid cancer Cancer Science 2005 96 3 143 148
170. Taniguchi M., Uehara Y., Matsuyama M., Takahashi M., Inhibition of ret tyrosine kinase activity by herbimycin A Biochemical and Biophysical Research Communications 1993 195 1 208 214 (Pubitemid 23266518)
171. Cassinelli G., Lanzi C., Pensa T., Clavilactones, a novel class of tyrosine kinase inhibitors of fungal origin Biochemical Pharmacology 2000 59 12 1539 1547
172. Strock C. J., Park J.-I., Rosen M., CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth Cancer Research 2003 63 17 5559 5563
173. Carlomagno F., Vitagliano D., Guida T., The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes Cancer Research 2002 62 4 1077 1082
174. Carlomagno F., Vitagliano D., Guida T., Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl) -7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2) Journal of Clinical Endocrinology and Metabolism 2003 88 4 1897 1902
175. Carlomagno F., Vitagliano D., Guida T., ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases Cancer Research 2002 62 24 7284 7290
176. Vidal M., Wells S., Ryan A., Cagan R., ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma Cancer Research 2005 65 9 3538 3541
177. Lanzi C., Cassinelli G., Pensa T., Inhibition of transforming activity of the Ret/Ptc1 oncoprotein by a 2-indolinone derivative International Journal of Cancer 2000 85 3 384 390
178. Lanzi C., Cassinelli G., Cuccuru G., Inactivation of Ret/Ptc1 oncoprotein and inhibition of papillary thyroid carcinoma cell proliferation by indolinone RPI-1 Cellular and Molecular Life Sciences 2003 60 7 1449 1459
179. Cuccuru G., Lanzi C., Cassinelli G., Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma Journal of the National Cancer Institute 2004 96 13 1006 1014
180. Wedge S. R., Ogilvie D. J., Dukes M., ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration Cancer Research 2002 62 16 4645 4655
181. Carlomagno F., Vitagliano D., Guida T., ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases Cancer Research 2002 62 24 7284 7290
182. Santoro M., Carlomagno F., Drug insight: small-molecule inhibitors of protein kinases in the treatment of thyroid cancer Nature Clinical Practice Endocrinology and Metabolism 2006 2 1 42 52
183. Carlomagno F., Anaganti S., Guida T., BAY 43-9006 inhibition of oncogenic RET mutants Journal of the National Cancer Institute 2006 98 5 326 334
184. Kim D. W., Jo Y. S., Jung H. S., An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases Journal of Clinical Endocrinology and Metabolism 2006 91 10 4070 4076
185. Hoffmann S., Burchert A., Wunderlich A., Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines Endocrine 2007 31 2 105 113
186. Polverino A., Coxon A., Starnes C., AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts Cancer Research 2006 66 17 8715 8721
187. Boughton D., Rosen L., Van Vugt A., Safety and antitumor activity of AMG 706 in patients with thyroid cancer: a subset analysis from a phase 1 dose-finding study Journal of Clinical Oncology 2006 24 18, supplement 3030
188. Gharib H., Goellner J. R., Fine-needle aspiration biopsy of the thyroid: an appraisal Annals of Internal Medicine 1993 118 4 282 289
189. Cohen Y., Rosenbaum E., Clark D. P., Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules Clinical Cancer Research 2004 10 8 2761 2765
190. Salvatore G., Giannini R., Faviana P., Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma Journal of Clinical Endocrinology and Metabolism 2004 89 10 5175 5180
191. Xing M., Tufano R. P., Tufaro A. P., Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer Journal of Clinical Endocrinology and Metabolism 2004 89 6 2867 2872
192. Chung K.-W., Yang S. K., Lee G. K., Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAFV600E mutation-prevalent area Clinical Endocrinology 2006 65 5 660 666
193. Kumagai A., Namba H., Akanov Z., Clinical implications of pre-operative rapid BRAF analysis for papillary thyroid cancer Endocrine Journal 2007 54 3 399 405
194. Jin L., Sebo T. J., Nakamura N., BRAF mutation analysis in fine needle aspiration (FNA) cytology of the thyroid Diagnostic Molecular Pathology 2006 15 3 136 143
195. Vitagliano D., Portella G., Troncone G., Thyroid targeting of the N-RAS(Gln61Lys) oncogene in transgenic mice results in follicular tumors that progress to poorly differentiated carcinomas Oncogene 2006 25 39 5467 5474
196. Nikiforova M. N., Zhao Wen Z., Robinson-Smith T., Molecular testing of thyroid FNA samples: feasibility and significance for preoperative diagnosis of thyroid tumors (abstract) Modern Pathology 2004 17 supplement 1 77A
197. Domingues R., Mendoa E., Sobrinho L., Bugalho M. J., Searching for RET/PTC rearrangements and BRAF V599E mutation in thyroid aspirates might contribute to establish a preoperative diagnosis of papillary thyroid carcinoma Cytopathology 2005 16 1 27 31
198. Nikiforova M. N., E Nikiforov Y., Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis Expert Review of Molecular Diagnostics 2008 8 1 83 95
199. Bounacer A., Wicker R., Caillou B., High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation Oncogene 1997 15 11 1263 1273
200. Elisei R., Romei C., Vorontsova T., RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults Journal of Clinical Endocrinology and Metabolism 2001 86 7 3211 3216
201. Nikiforova M. N., Caudill C. M., Biddinger P., Nikiforov Y. E., Prevalence of RET/PTC rearrangements in Hashimotos thyroiditis and papillary thyroid carcinomas International Journal of Surgical Pathology 2002 10 1 15 22
202. Nikiforova M. N., Biddinger P. W., Caudill C. M., Kroll T. G., Nikiforov Y. E., PAX8-PPAR rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses American Journal of Surgical Pathology 2002 26 8 1016 1023
203. Castro P., Rebocho A. P., Soares R. J., PAX8-PPAR rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma Journal of Clinical Endocrinology and Metabolism 2006 91 1 213 220
204. Gustafson K. S., LiVolsi V. A., Furth E. E., Pasha T. L., Putt M. E., Baloch Z. W., Peroxisome proliferator-activated receptor expression in follicular-patterned thyroid lesions. Caveats for the use of immunohistochemical studies American Journal of Clinical Pathology 2003 120 2 175 181